Benefits from treatment and control of patients with resistant hypertension

International Journal of Hypertension

Volumn 2011, Issue , 2011, Pages

  Doumas, Michael ^a   Papademetriou, Vasilios ^b   Douma, Stella ^c   Faselis, Charles ^a   Tsioufis, Konstantinos ^b   Gkaliagkousi, Eugene ^c   Petidis, Konstantinos ^c   Zamboulis, Chrysanthos ^c  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; SPIRONOLACTONE;

AUTONOMIC DENERVATION; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL STUDY; COHORT ANALYSIS; DISEASE CONTROL; HUMAN; INTERVENTION STUDY; MALIGNANT HYPERTENSION; OBSERVATIONAL STUDY; PRESSORECEPTOR; PREVALENCE; PRIORITY JOURNAL; RESISTANT HYPERTENSION; REVIEW; RISK ASSESSMENT; SYMPATHECTOMY;

EID: 82255184525     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.4061/2011/318549     Document Type: Review

References (64)

1. Calhoun D. A., Jones D., Textor S., Resistant hypertension: diagnosis, evaluation and treatment. Hypertension 2008 117 510 526
2. Sarafidis P. A., Bakris G. L., Resistant hypertension: an overview of evaluation and treatment. Journal of the American College of Cardiology 2008 52 22 1749 1757 2-s2.0-56149084750 10.1016/j.jacc.2008.08.036
3. Pimenta E., Gaddam K. K., Oparil S., Aban I., Husain S., Dell'Italia L. J., Calhoun D. A., Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009 54 3 475 481 2-s2.0-70349249634 10.1161/HYPERTENSIONAHA.109. 131235
4. Douma S., Petidis K., Doumas M., Papaefthimiou P., Triantafyllou A., Kartali N., Papadopoulos N., Vogiatzis K., Zamboulis C., Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. The Lancet 2008 371 9628 1921 1926 2-s2.0-44649150565 10.1016/S0140-6736(08)60834-X (Pubitemid 351778191)
5. Nishizaka M. K., Zaman M. A., Calhoun D. A., Efficacy of low-dose spironolactone in subjects with resistant hypertension. American Journal of Hypertension 2003 16 11 I 925 930 2-s2.0-0142231538 10.1016/S0895-7061(03)01032- X (Pubitemid 37315491)
6. Mahmud A., Mahgoub M., Hall M., Feely J., Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? American Journal of Hypertension 2005 18 12 1631 1635 2-s2.0-29144455401 10.1016/j.amjhyper.2005.06.010 (Pubitemid 41814688)
7. Sharabi Y., Adler E., Shamis A., Nussinovitch N., Markovitz A., Grossman E., Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. American Journal of Hypertension 2006 19 7 750 755 2-s2.0-33745273601 10.1016/j.amjhyper.2005.11.016 (Pubitemid 43928519)
8. De Souza F., Muxfeldt E., Fiszman R., Salles G., Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010 55 1 147 152 2-s2.0-73849140879 10.1161/HYPERTENSIONAHA.109. 140988
9. Lane D. A., Shah S., Beevers D. G., Low-dose spironolactone in the management of resistant hypertension: a surveillance study. Journal of Hypertension 2007 25 4 891 894 2-s2.0-33947162019 10.1097/HJH.0b013e328014954d (Pubitemid 46398886)
10. Chapman N., Dobson J., Wilson S., Dahlöf B., Sever P. S., Wedel H., Poulter N. R., Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007 49 4 839 845 2-s2.0-34047197931 10.1161/01.HYP.0000259805.18468.8c (Pubitemid 351664214)
11. Parthasarathy H. K., Alhashmi K., McMahon A. D., Struthers A. D., McInnes G. T., Ford I., Connell J. M., MacDonald T. M., Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. Journal of Hypertension 2010 28 1 170 177 2-s2.0-73849092227 10.1097/HJH.0b013e328332b79b
12. Volhard F., Fahr T., Die Brightsche Nierenkrankheit, Klinik, Pathologie und Atlas 1914 Berlin, Germany Springer 210 246
13. Wagener H. P., The retinitis of malignant hypertension. Transactions of the American Ophthalmological Society 1927 25 349 380
14. Keith N. M., Wagener H. P., Kernohan J. W., The syndrome of malignant hypertension. Archives of Internal Medicine 1928 41 141 157
15. Hood B., Harington M., Five and a half years experience of combination of antihypertensive drugs: main present difficulties. Hypotensive Drugs 1956 New York, NY, USA Pergamon Press 135 148
16. Kincaid-Smith P., McMichael J., Murphy E. A., The clinical course and pathology of hypertension with papilloedema (malignant hypertension). The Quarterly Journal of Medicine 1958 27 105 117 153 2-s2.0-0001449470
17. Schottstaedt M. F., Sokolow M., The natural history and course of hypertension with papilledema (Malignant Hypertension). American Heart Journal 1953 45 3 331 362 2-s2.0-0342708474
18. Perry H. M. Jr., Schroeder H. A., The effect of treatment on mortality rates in severe hypertension; a comparison of medical and surgical regimens. A.M.A. Archives of Internal Medicine 1958 102 3 418 425 2-s2.0-0000933383
19. Mosenthal H. O., Clinical aspects of hypertension including malignant hypertension. Bulletin of the New York Academy of Medicine 1938 14 349 360
20. Howard C. P., The diagnosis and treatment of malignant hypertension. Canadian Medical Association Journal 1935 32 621 624
21. Simpson F. O., Smirk F. H., The treatment of malignant hypertension. The American Journal of Cardiology 1962 9 6 868 873 2-s2.0-50549190497
22. Grobin W., Malignant hypertension and its treatment. Canadian Medical Association Journal 1960 82 600 601
23. Bulpitt C. J., Prognosis of treated hypertension 19511981. British Journal of Clinical Pharmacology 1982 13 1 73 79 2-s2.0-0020406063
24. Greenwood B., The origins of sympathectomy. Medical History 1967 11 2 165 169 2-s2.0-0014078135
25. Keith N. M., Wagener H. P., Barker N. W., Some different types of essential hypertension: their course and prognosis. American Journal of the Medical Sciences 1974 268 6 336 345 2-s2.0-0016329387
26. Peet M. M., Woods W. W., Braden B., The surgical treatment of hypertension. The Journal of the American Medical Association 1940 115 1875 1885
27. Page I. H., Heuer G. J., A surgical treatment of essential hypertension. The Journal of Clinical Investigation 1935 14 22 26
28. Smithwick R. H., Surgical treatment of hypertension. The American Journal of Medicine 1948 4 5 744 759 2-s2.0-3342907322
29. Isberg E. M., Peet M. M., The influence of supradiaphragmatic splanchnicectomy on the heart in hypertension. American Heart Journal 1948 35 4 567 583 2-s2.0-50349141721
30. Allen E. V., Sympathectomy for essential hypertension. Circulation 1952 6 1 131 140 2-s2.0-75349098765
31. Whitelaw G. P., Kinsey D., Smithwick R. H., Factors influencing the choice of treatment in essential hypertension. Surgical, medical or a combination of both. The American Journal of Surgery 1964 107 1 220 231 2-s2.0-50549198677
32. Hammarström S., Bechgaard P., Prognosis in arterial hypertension. Comparison between 251 patients after sympathectomy and a selected series of 435 non-operated patients. The American Journal of Medicine 1950 8 1 53 56 2-s2.0-50349122148
33. Evans J. A., The place of splanchnicectomy in the treatment of hypertension. Canadian Medical Association journal 1951 64 1 47 50 2-s2.0-76549235121
34. Hinton J. W., End results of thoracolumbar sympathectomy for advanced essential hypertension. California Medicine 1949 70 4 282 287
35. Grimson K. S., Orgain E. S., Anderson B., Results of treatment of patients with hypertension by total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy. Annals of Surgery 1949 129 850 871
36. Harland J. C., d'Abreu F., Lumbodorsal sympathectomy in severe hypertension. British Medical Journal 1949 1 1019 1024
37. Chris S. M., Sympathectomy for hypertension. British medical journal 1951 1 4708 665 670 2-s2.0-9044244227
38. Doumas M., Faselis C., Papademetriou V., Renal sympathetic denervation and systemic hypertension. American Journal of Cardiology 2010 105 4 570 576 2-s2.0-75349085866 10.1016/j.amjcard.2009.10.027
39. Smithwick R. H., Thompson J. E., Splanchnicectomy for essential hypertension; results in 1,266 cases. Journal of the American Medical Association 1953 152 16 1501 1504 2-s2.0-0000220091
40. Harington M., Kincaid-Smith P., McMichael J., Results of treatment in malignant hypertension: a seven-year experience in 94 cases. British Medical Journal 1959 2 5158 969 980 2-s2.0-0000102102
41. Goldring W., Chasis H., Ingelfinger F. J., Relman A. S., Finland M., Antihypertensive drug therapy. Controversy in Internal Medicine 1966 Philadelfia, Pa, USA WB Saunders 83 91
42. Osler W., Am address on high blood pressure: its associations, advantages, and disadvantages. British Medical Journal 1912 2 1173 1177
43. Veterans Administration Cooperative Study Group on Antihypertensive Agents, Effects of treatment on morbidity and mortality in hypertension: results in patients with diastolic blood pressures averaging 115-129 mmHg. The Journal of the American Medical Association 1967 202 116 122
44. Reader R., Bauer G. E., Doyle A. E., The Australian therapeutic trial in mild hypertension. Report by the Management Committee. The Lancet 1980 1 8181 1261 1267 2-s2.0-0018817460 (Pubitemid 10118230)
45. Korner P. I., Bauer G. E., Doyle A. E., Untreated mild hypertension. A report by the management committee of the Australian therapeutic trial in mild hypertension. The Lancet 1982 1 8265 185 191 2-s2.0-0020086367 (Pubitemid 12212898)
46. The Management Committee of the Australian National Blood Pressure Study, Prognostic factors in the treatment of mild hypertension. Circulation 1984 69 668 676
47. Isaksson H., Ostergren J., Prognosis in therapy-resistant hypertension. Journal of Internal Medicine 1994 236 6 643 649 2-s2.0-0028559236
48. Redon J., Campos C., Narciso M. L., Rodicio J. L., Pascual J. M., Ruilope L. M., Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998 31 2 712 718 2-s2.0-0031933420
49. Pierdomenico S. D., Lapenna D., Bucci A., Di Tommaso R., Di Mascio R., Manente B. M., Caldarella M. P., Neri M., Cuccurullo F., Mezzetti A., Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. American Journal of Hypertension 2005 18 11 1422 1428 2-s2.0-27644538062 10.1016/j.amjhyper.2005.05. 014 (Pubitemid 41566669)
50. Salles G. F., Cardoso C. R. L., Muxfeldt E. S., Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Archives of Internal Medicine 2008 168 21 2340 2346 2-s2.0-57149138527
51. Muxfeldt E. S., Cardoso C. R. L., Salles G. F., Prognostic value of nocturnal blood pressure reduction in resistant hypertension. Archives of Internal Medicine 2009 169 9 874 880 2-s2.0-66149155023 10.1001/archinternmed. 2009.68
52. Muxfeldt E. S., Cardoso C. R. L., Dias V. B., Nascimento A. C. M., Salles G. F., Prognostic impact of the ambulatory arterial stiffness index in resistant hypertension. Journal of Hypertension 2010 28 7 1547 1553 2-s2.0-77954384520 10.1097/HJH.0b013e328339f9e5
53. Salles G. F., Cardoso C. R. L., Fiszman R., Muxfeldt E. S., Prognostic significance of baseline and serial changes in electrocardiographic strain pattern in resistant hypertension. Journal of Hypertension 2010 28 1715 1723 2-s2.0-77953299904 10.1097/HJH.0b013e32833af39a
54. Salles G. F., Cardoso C. R. L., Muxfeldt E. S., Prognostic value of ventricular repolarization prolongation in resistant hypertension: a prospective cohort study. Journal of Hypertension 2009 27 5 1094 1101 2-s2.0-67649644426 10.1097/HJH.0b013e32832720b3
55. Magnanini M. M. F., Nogueira A. D. R., Carvalho M. S., Bloch K. V., Ambulatory blood pressure monitoring and cardiovascular risk in resistant hypertensive women. Arquivos Brasileiros de Cardiologia 2009 92 6 448 489 2-s2.0-68049113259 10.1590/S0066-782X2009000600012
56. Benetos A., Thomas F., Bean K., Gautier S., Smulyan H., Guize L., Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Archives of Internal Medicine 2002 162 5 577 581 2-s2.0-0036190493 (Pubitemid 34193545)
57. Perry H. M., Miller J. P., Fornoff J. R., Baty J. D., Sambhi M. P., Rutan G., Moskowitz D. W., Carmody S. E., Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995 25 4 I 587 594 2-s2.0-0028953319
58. Dahlöf B., Sever P. S., Poulter N. R., Wedel H., Beevers D. G., Caulfield M., Collins R., Kjeldsen S. E., Kristinsson A., McInnes G. T., Mehlsen J., Nieminen M., O'Brien E., Östergren J., Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The Lancet 2005 366 9489 895 906 2-s2.0-24644443331 10.1016/S0140-6736(05)67185-1 (Pubitemid 41265663)
59. Jamerson K., emarshal@umich.edu Weber M. A., Bakris G. L., Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. The New England Journal of Medicine 2008 359 23 2417 2428 10.1056/NEJMoa0806182
60. Furberg C. D., Wright J. T. Jr., jxw20@po.cwru.edu Davis B. R., bdavis@sph.uth.tmc.edu Cutler J. A., Alderman M., Black H., Cushman W., Grimm R., Haywood L. J., Leenen F., Oparil S., Probstfield J., Whelton P., Nwachuku C., Gordon D., Proschan M., Einhom P., Ford C. E., Piller L. B., Dunn I. K., Goff D., Pressel S., Bettencourt J., DeLeon B., Simpson L. M., Blanton J., Geraci T., Walsh S. M., Nelson C., Rahman M., Juratovac A., Pospisil R., Carroll L., Sullivan S., Russo J., Barone G., Christian R., Feldman S., Lucente T., Calhoun D., Jenkins K., McDowell P., Johnson J., Kingry C., Alzate J., Margolis K. L., Holland-Klemme L. A., Jaeger B., Williamson J., Louis G., Ragusa P., Williard A., Ferguson R. L.S., Tanner J., Eckfeldt J., Crow R., Pelosi J., Major outcomes in high-risk hypertensive patients randomized to angiotensin- converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Journal of the American Medical Association 2002 288 23 2981 2997 10.1001/jama.288.23.2981 (Pubitemid 35471160)
61. Weber M. A., Black H., Bakris G., Krum H., Linas S., Weiss R., Linseman J. V., Wiens B. L., Warren M. S., Lindholm L. H., A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. The Lancet 2009 374 9699 1423 1431 2-s2.0-70350133404 10.1016/S0140-6736(09)61500-2
62. Bakris G. L., gbakris@gmail.com Lindholm L. H., Black H. R., Krum H., Linas S., Linseman J. V., Arterburn S., Sager P., Weber M., Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 2010 56 5 824 830 10.1161/HYPERTENSIONAHA.110. 156976
63. Scheffers I. J. M., Kroon A. A., Schmidli J., Jordan J., Tordoir J. J. M., Mohaupt M. G., Luft F. C., Haller H., Menne J., Engeli S., Ceral J., Eckert S., Erglis A., Narkiewicz K., Philipp T., De Leeuw P. W., p.deleeuw@intmed. unimaas.nl Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. Journal of the American College of Cardiology 2010 56 15 1254 1258 10.1016/j.jacc.2010.03.089
64. Krum H., Schlaich M., Whitbourn R., Sobotka P. A., Sadowski J., Bartus K., Kapelak B., Walton A., Sievert H., Thambar S., Abraham W. T., Esler M., Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. The Lancet 2009 373 9671 1275 1281 2-s2.0-64049084640 10.1016/S0140-6736(09)60566-3